Ventoux Biosciences

Executive Summary

Ventoux Biosciences is a preclinical-stage biotech company pioneering immune-fibrotic therapies for disease and injury. Founded in 2020 and headquartered in San Diego, the company leverages AI-guided multi-omic analysis to identify novel targets modulating the immune-fibrotic axis. Its lead candidate, VEN-201, targets two high-need indications: Dupuytren's disease and spinal cord injury. By addressing the underlying fibrotic and immune pathways, Ventoux aims to provide first-in-class, non-surgical treatment options that could preserve function and improve outcomes. The company's platform offers potential for expansion into other fibrotic conditions, positioning it as an innovative player in the cardiovascular and metabolic disease space, despite its early stage. Ventoux faces typical risks of preclinical companies, including the need for substantial funding to advance VEN-201 through IND-enabling studies and into clinical trials. The lack of disclosed financing and valuation data adds uncertainty, though the AI-driven target discovery approach may attract partnerships. Success in upcoming preclinical studies and potential IND filing will be critical milestones. If VEN-201 demonstrates efficacy and safety in animal models, the company could emerge as a candidate for further development or acquisition. The next 12-18 months will be pivotal in validating its platform and advancing toward clinical testing.

Upcoming Catalysts (preview)

• H2 2026Preclinical efficacy data for VEN-201 in Dupuytren's disease model50% success
• 2027IND-enabling toxicology studies for spinal cord injury indication40% success
• TBDPartnership or licensing deal for immune-fibrotic platform30% success